The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
Recent advances in BPDCN: tagraxofusp, pivekimab sunirine and emerging therapeutic strategies
Naveen Pemmaraju, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, reviews recent advances in blastic plasmacytoid dendritic cell neoplasm (BPDCN), including the two FDA-approved CD123-targeted agents, tagraxofusp and pivekimab sunirine. Dr Pemmaraju highlights their efficacy and key toxicities, triplet combinations, CNS involvement, and emerging targets and resistance mechanisms. This presentation took place at the 4th International Workshop on Myelodysplastic Syndromes & Myeloproliferative Neoplasms (iwMDS/iwMPN) 2026, held in Washington, DC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
